CEBPZ and acute myeloid leukemia: A more recent report from CALBG confirmed that among younger patients (<60 years) with CBF-AML, those treated with multicourse HDAC (n = 149) in remission were less likely to relapse (P < 0.001) compared to ones treated with a single course of HDAC (n = 48) [17].